Lymphoseek Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6409990 CARDINAL HEALTH 414 Macromolecular carrier for drug and diagnostic agent delivery
May, 2025

(1 year, 7 months from now)

US9439985 CARDINAL HEALTH 414 Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Jan, 2029

(5 years from now)

Lymphoseek Kit is owned by Cardinal Health 414.

Lymphoseek Kit contains Technetium Tc-99M Tilmanocept.

Lymphoseek Kit has a total of 2 drug patents out of which 0 drug patents have expired.

Lymphoseek Kit was authorised for market use on 13 March, 2013.

Lymphoseek Kit is available in injectable;injection dosage forms.

The generics of Lymphoseek Kit are possible to be released after 30 January, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 19, 2024

Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient

Market Authorisation Date: 13 March, 2013

Treatment: NA


More Information on Dosage

LYMPHOSEEK KIT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic